-
A pilot study of the functionality and clinician acceptance of a clinical decision support tool to improve primary care of opioid use disorder.
Rossom RC, Sperl-Hillen JM, O'Connor PJ, Crain AL, Nightingale L, Pylkas A, Huntley KV, Bart G. A pilot study of the functionality and clinician acceptance of a clinical decision support tool to improve primary care of opioid use disorder. Addiction Science & Clinical Practice 2021;16:37.
-
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: A secondary analysis.
Murphy SM, Jeng PJ, McCollister KE, Leff JA, Jalali A, Shulman M, Lee JD, Nunes EV, Novo P, Rotrosen J, Schackman BR. Cost-Effectiveness Implications of Increasing the Efficiency of the Extended-Release Naltrexone Induction Process for the Treatment of Opioid Use Disorder: A Secondary Analysis. Addiction 2021;116(12):3444-3453.
-
Comparison of methods for alcohol and drug screening in primary care clinics.
McNeely J, Adam A, Rotrosen J, Wakeman SE, Wilens TE, Kannry J, Rosenthal RN, Wahle A, Pitts S, Farkas S, Rosa CL, Peccoralo LA, Waite E, Vega A, Kent J, Craven CK, Kaminski TA, Firmin E, Isenberg B, Harris M, Kushninuk A, Hamilton L. Comparison of methods for alcohol and drug screening in primary care clinics. JAMA Network Open 2021;4(5):e2110721.
-
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.
Greiner MG, Shulman M, Choo T, Scodes J, Pavlicova M, Campbell ANC, Novo P, Fishman MJ, Lee JD, Rotrosen J, Nunes EV. Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse. Journal of Substance Abuse Treatment 2021;131:108447.
-
The NIDA Clinical Trials Network: Evolving, expanding, and addressing the opioid epidemic.
Tai B, Dobbins R, Liu D, Moran L. The NIDA Clinical Trials Network: Evolving, expanding, and addressing the opioid epidemic. Addiction Science & Clinical Practice 2021;16:28.
-
Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network trial [commentary].
Hser Y, Ober AJ, Dopp AR, Lin C, Osterhage KP, Clingan SE, Mooney LJ, Curtis ME, Marsch LA, McLeman B, Hichborn E, Lester LS, Baldwin L, Liu Y, Jacobs P, Saxon AJ. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network trial [commentary]. Addiction Science & Clinical Practice 2021;16:24.
-
The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation.
D'Onofrio G, Hawk KF, Herring A, Perrone J, Cowan E, McCormack R, Dziura J, Taylor A, Coupet E, Edelman EJ, Pantalon MV, Owens PH, Martel SH, O'Connor PG, VanVeldhuisen P, DeVogel N, Huntley K, Murphy SM, Lofwall MR, Walsh SL, Fiellin DA. The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation. Contemporary Clinical Trials 2021;104:106359.
-
Recent and active problematic substance use among primary care patients: Results from the Alcohol, Smoking, and Substance Involvement Screening Test in a multisite study.
John WS, Zhu H, Greenblatt LH, Wu L. Recent and Active Problematic Substance Use Among Primary Care Patients: Results from the Alcohol, Smoking, and Substance Involvement Screening Test in a Multisite Study. Substance Abuse 2021;42(4):487-492
-
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD).”
Shulman M, Weiss RD, Rotrosen J, Novo P, Costello E, Nunes EV. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)." Addiction Science & Clinical Practice 2021;16:15.
-
Implementation facilitation to introduce and support emergency department-initiated buprenorphine for opioid use disorder in high need, low resource settings: Protocol for multi-site implementation-feasibility study.
McCormack R, Rotrosen J, Gauthier P, D'Onofrio G, Fiellin DA, Marsch LA, Novo P, Liu D, Edelman EJ, Farkas S, Matthews AG, Mulatya C, Salazar D, Wolff J, Knight R, Goodman W, Hawk K. Implementation facilitation to introduce and support emergency department-initiated buprenorphine for opioid use disorder in high need, low resource settings: Protocol for multi-site implementation-feasibility study. Addiction Science & Clinical Practice, 2021;16:16.